Connect your AI

Azenta AZTA Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

BioLife SolutionsBLFS

——

Other financials

Income statement

Revenue$144.8M+1.0%

Gross profit$62.0M-1.2%

Operating income-$165.8M-811%

Net income-$160.8M-237%

EPS (diluted)-$3.49-236%

Balance sheet

Cash & equivalents$125.2M—

Total debt$55.7M—

Total equity$1.6B-8.3%

Total assets$1.9B—

Cash flow

Operating cash flow$13.5M-6.2%

CapEx$7.4M-0.1%

Free cash flow$6.1M-12.7%

Valuation

Market cap$1.14B-16.3%

Enterprise value$1.07B—

P/S1.9×-0.2×

Profitability

Gross margin40%-1.0pp

Operating margin-31.6%-59.7pp

Net margin-29.1%-80.7pp

FCF margin8.6%—

Returns & leverage

Return on equity-10.7%-22.4pp

Debt / equity0×—

Current ratio2.8×—

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Azenta's cash cash equivalents and short term investments?: Azenta (AZTA) reported cash cash equivalents and short term investments of $564.84M in Q1 2026.